Correlation Between Halozyme Therapeutics and Edgewise Therapeutics

Can any of the company-specific risk be diversified away by investing in both Halozyme Therapeutics and Edgewise Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Halozyme Therapeutics and Edgewise Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Halozyme Therapeutics and Edgewise Therapeutics, you can compare the effects of market volatilities on Halozyme Therapeutics and Edgewise Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Halozyme Therapeutics with a short position of Edgewise Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Halozyme Therapeutics and Edgewise Therapeutics.

Diversification Opportunities for Halozyme Therapeutics and Edgewise Therapeutics

0.32

Correlation Coefficient

Halozyme Therapeutics  Edgewise Therapeutics

Weak diversification

The 3 months correlation between Halozyme and Edgewise is 0.32. Overlapping area represents the amount of risk that can be diversified away by holding Halozyme Therapeutics and Edgewise Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Edgewise Therapeutics and Halozyme Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Halozyme Therapeutics are associated (or correlated) with Edgewise Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Edgewise Therapeutics has no effect on the direction of Halozyme Therapeutics i.e., Halozyme Therapeutics and Edgewise Therapeutics go up and down completely randomly.

Pair Corralation between Halozyme Therapeutics and Edgewise Therapeutics

Given the investment horizon of 90 days Halozyme Therapeutics is expected to generate 0.85 times more return on investment than Edgewise Therapeutics. However, Halozyme Therapeutics is 1.18 times less risky than Edgewise Therapeutics. It trades about -0.13 of its potential returns per unit of risk. Edgewise Therapeutics is currently generating about -0.13 per unit of risk. If you would invest  5,872  in Halozyme Therapeutics on October 6, 2024 and sell it today you would lose (1,098) from holding Halozyme Therapeutics or give up 18.7% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Halozyme Therapeutics  vs.  Edgewise Therapeutics

Halozyme Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Halozyme Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's essential indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Edgewise Therapeutics

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Edgewise Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Edgewise Therapeutics is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Halozyme Therapeutics and Edgewise Therapeutics

The main advantage of trading using opposite Halozyme Therapeutics and Edgewise Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Halozyme Therapeutics position performs unexpectedly, Edgewise Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edgewise Therapeutics will offset losses from the drop in Edgewise Therapeutics' long position.

The idea behind Halozyme Therapeutics and Edgewise Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.